Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

A Cell Line for Detection of Botulinum Neurotoxin Type B.

Rust A, Doran C, Hart R, Binz T, Stickings P, Sesardic D, Peden AA, Davletov B.

Front Pharmacol. 2017 Nov 9;8:796. doi: 10.3389/fphar.2017.00796. eCollection 2017.

2.

The European AntibotABE Framework Program and Its Update: Development of Innovative Botulinum Antibodies.

Rasetti-Escargueil C, Avril A, Miethe S, Mazuet C, Derman Y, Selby K, Thullier P, Pelat T, Urbain R, Fontayne A, Korkeala H, Sesardic D, Hust M, Popoff MR.

Toxins (Basel). 2017 Oct 2;9(10). pii: E309. doi: 10.3390/toxins9100309. Review.

3.

Immuno-detection of cleaved SNAP-25 from differentiated mouse embryonic stem cells provides a sensitive assay for determination of botulinum A toxin and antitoxin potency.

Yadirgi G, Stickings P, Rajagopal S, Liu Y, Sesardic D.

J Immunol Methods. 2017 Dec;451:90-99. doi: 10.1016/j.jim.2017.09.007. Epub 2017 Sep 21.

4.

SiMa Cells for a Serotype Specific and Sensitive Cell-Based Neutralization Test for Botulinum Toxin A and E.

Bak N, Rajagopal S, Stickings P, Sesardic D.

Toxins (Basel). 2017 Jul 20;9(7). pii: E230. doi: 10.3390/toxins9070230.

5.

Assessment of ELISA as endpoint in neuronal cell-based assay for BoNT detection using hiPSC derived neurons.

Pellett S, Tepp WH, Johnson EA, Sesardic D.

J Pharmacol Toxicol Methods. 2017 Nov;88(Pt 1):1-6. doi: 10.1016/j.vascn.2017.04.013. Epub 2017 Apr 29.

6.

Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature.

Peck MW, Smith TJ, Anniballi F, Austin JW, Bano L, Bradshaw M, Cuervo P, Cheng LW, Derman Y, Dorner BG, Fisher A, Hill KK, Kalb SR, Korkeala H, Lindström M, Lista F, Lúquez C, Mazuet C, Pirazzini M, Popoff MR, Rossetto O, Rummel A, Sesardic D, Singh BR, Stringer SC.

Toxins (Basel). 2017 Jan 18;9(1). pii: E38. doi: 10.3390/toxins9010038. Review.

7.

Collaborative study for the calibration of a replacement International Standard for diphtheria toxoid for use in flocculation test.

Coombes L, Rigsby P, Sesardic D, Stickings P.

Biologicals. 2016 Nov;44(6):556-566. doi: 10.1016/j.biologicals.2016.07.005. Epub 2016 Sep 30.

8.

Neutralization of Botulinum Neurotoxin Type E by a Humanized Antibody.

Derman Y, Selby K, Miethe S, Frenzel A, Liu Y, Rasetti-Escargueil C, Avril A, Pelat T, Urbain R, Fontayne A, Thullier P, Sesardic D, Lindström M, Hust M, Korkeala H.

Toxins (Basel). 2016 Sep 12;8(9). pii: E257. doi: 10.3390/toxins8090257.

9.

Development of Germline-Humanized Antibodies Neutralizing Botulinum Neurotoxin A and B.

Miethe S, Mazuet C, Liu Y, Tierney R, Rasetti-Escargueil C, Avril A, Frenzel A, Thullier P, Pelat T, Urbain R, Fontayne A, Sesardic D, Hust M, Popoff MR.

PLoS One. 2016 Aug 25;11(8):e0161446. doi: 10.1371/journal.pone.0161446. eCollection 2016.

10.

Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples.

Simon S, Fiebig U, Liu Y, Tierney R, Dano J, Worbs S, Endermann T, Nevers MC, Volland H, Sesardic D, Dorner MB.

Toxins (Basel). 2015 Nov 26;7(12):5011-34. doi: 10.3390/toxins7124860.

11.

Development of Human-Like scFv-Fc Neutralizing Botulinum Neurotoxin E.

Miethe S, Rasetti-Escargueil C, Avril A, Liu Y, Chahboun S, Korkeala H, Mazuet C, Popoff MR, Pelat T, Thullier P, Sesardic D, Hust M.

PLoS One. 2015 Oct 6;10(10):e0139905. doi: 10.1371/journal.pone.0139905. eCollection 2015.

12.

Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain.

Avril A, Miethe S, Popoff MR, Mazuet C, Chahboun S, Rasetti-Escargueil C, Sesardic D, Thullier P, Hust M, Pelat T.

BMC Biotechnol. 2015 Sep 17;15:86. doi: 10.1186/s12896-015-0206-0.

13.

Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B.

Rasetti-Escargueil C, Avril A, Chahboun S, Tierney R, Bak N, Miethe S, Mazuet C, Popoff MR, Thullier P, Hust M, Pelat T, Sesardic D.

MAbs. 2015;7(6):1161-77. doi: 10.1080/19420862.2015.1082016. Epub 2015 Sep 18.

14.

Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library.

Miethe S, Rasetti-Escargueil C, Liu Y, Chahboun S, Pelat T, Avril A, Frenzel A, Schirrmann T, Thullier P, Sesardic D, Hust M.

MAbs. 2014 Mar-Apr;6(2):446-59. doi: 10.4161/mabs.27773. Epub 2014 Jan 9.

15.

Calibration and commutability assessment of the 1st International Standard for Diphtheria Antitoxin Human.

Stickings P, Rigsby P, Coombes L, von Hunolstein C, Ralli L, Pinto A, Sesardic D.

Biologicals. 2013 Nov;41(6):384-92. doi: 10.1016/j.biologicals.2013.08.001. Epub 2013 Sep 5.

PMID:
24011675
16.

Synthetic self-assembling clostridial chimera for modulation of sensory functions.

Ferrari E, Gu C, Niranjan D, Restani L, Rasetti-Escargueil C, Obara I, Geranton SM, Arsenault J, Goetze TA, Harper CB, Nguyen TH, Maywood E, O'Brien J, Schiavo G, Wheeler DW, Meunier FA, Hastings M, Edwardson JM, Sesardic D, Caleo M, Hunt SP, Davletov B.

Bioconjug Chem. 2013 Oct 16;24(10):1750-9. doi: 10.1021/bc4003103. Epub 2013 Sep 20.

17.

In vitro antigen ELISA for quality control of tetanus vaccines.

Coombes L, Tierney R, Rigsby P, Sesardic D, Stickings P.

Biologicals. 2012 Nov;40(6):466-72. doi: 10.1016/j.biologicals.2012.07.011. Epub 2012 Aug 13.

PMID:
22898438
18.

A single-dose cytomegalovirus-based vaccine encoding tetanus toxin fragment C induces sustained levels of protective tetanus toxin antibodies in mice.

Tierney R, Nakai T, Parkins CJ, Caposio P, Fairweather NF, Sesardic D, Jarvis MA.

Vaccine. 2012 Apr 26;30(20):3047-52. doi: 10.1016/j.vaccine.2012.02.043. Epub 2012 Mar 10.

PMID:
22414558
19.

A functional dual-coated (FDC) microtiter plate method to replace the botulinum toxin LD50 test.

Liu YY, Rigsby P, Sesardic D, Marks JD, Jones RG.

Anal Biochem. 2012 Jun 1;425(1):28-35. doi: 10.1016/j.ab.2012.02.038. Epub 2012 Mar 6.

PMID:
22406430
20.

Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin.

Chahboun S, Hust M, Liu Y, Pelat T, Miethe S, Helmsing S, Jones RG, Sesardic D, Thullier P.

BMC Biotechnol. 2011 Nov 23;11:113. doi: 10.1186/1472-6750-11-113.

21.

Collaborative study for the calibration of a replacement International Standard for Tetanus Toxoid Adsorbed.

Tierney R, Stickings P, Hockley J, Rigsby P, Iwaki M, Sesardic D.

Biologicals. 2011 Nov;39(6):404-16. doi: 10.1016/j.biologicals.2011.09.007. Epub 2011 Oct 8.

PMID:
21985899
22.

Calibration of the Ph. Eur. Biological Reference Preparation (BRP) for tetanus vaccine (adsorbed) batch 3.

Tierney R, Hockley J, Rigsby P, Terao E, Daas A, Buchheit KH, Sesardic D.

Pharmeur Bio Sci Notes. 2011 Jun;2011(1):1-26.

PMID:
21619853
23.

Phrenic nerve-hemidiaphragm as a highly sensitive replacement assay for determination of functional botulinum toxin antibodies.

Rasetti-Escargueil C, Liu Y, Rigsby P, Jones RG, Sesardic D.

Toxicon. 2011 Jun;57(7-8):1008-16. doi: 10.1016/j.toxicon.2011.04.003. Epub 2011 Apr 13.

PMID:
21513727
24.

Release of proteolytic activity following reduction in therapeutic human serum albumin containing products: detection with a new neoepitope endopeptidase immunoassay.

Jones RG, Liu Y, Halls C, Thorpe SJ, Longstaff C, Matejtschuk P, Sesardic D.

J Pharm Biomed Anal. 2011 Jan 5;54(1):74-80. doi: 10.1016/j.jpba.2010.08.013. Epub 2010 Aug 19.

PMID:
20832960
25.

The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. The report and recommendations of a ZEBET Expert Meeting.

Adler S, Bicker G, Bigalke H, Bishop C, Blümel J, Dressler D, Fitzgerald J, Gessler F, Heuschen H, Kegel B, Luch A, Milne C, Pickett A, Ratsch H, Ruhdel I, Sesardic D, Stephens M, Stiens G, Thornton PD, Thürmer R, Vey M, Spielmann H, Grune B, Liebsch M.

Altern Lab Anim. 2010 Aug;38(4):315-30. No abstract available.

PMID:
20822324
26.

Is it possible to accurately determine content of botulinum neurotoxin type A in drug products?

Sesardic D.

Drugs R D. 2010;10(2):91-2. doi: 10.2165/11584910-000000000-00000. No abstract available.

27.

Collaborative study for the calibration of a replacement international standard for diphtheria toxoid adsorbed.

Stickings P, Rigsby P, Coombes L, Malik K, Matejtschuk P, Sesardic D.

Biologicals. 2010 Sep;38(5):529-38. doi: 10.1016/j.biologicals.2010.04.001. Epub 2010 Jun 19.

PMID:
20646934
28.

External quality assessment for the determination of diphtheria antitoxin in human serum.

Di Giovine P, Pinto A, Olander RM, Sesardic D, Stickings P, Berbers G, Neal S, Efstratiou A, Paberza R, Dauksiene S, Bujko M, Detcheva A, Joks U, Levent B, von Hunolstein C.

Clin Vaccine Immunol. 2010 Aug;17(8):1282-90. doi: 10.1128/CVI.00096-10. Epub 2010 Jul 7.

29.

Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.

Held DM, Shurtleff AC, Fields S, Green C, Fong J, Jones RG, Sesardic D, Buelow R, Burke RL.

Clin Vaccine Immunol. 2010 Jun;17(6):930-6. doi: 10.1128/CVI.00493-09. Epub 2010 Apr 21.

30.

Collaborative study on a Guinea pig serological method for the assay of acellular pertussis vaccines.

Winsnes R, Sesardic D, Daas A, Terao E, Behr-Gross ME.

Pharmeur Bio Sci Notes. 2009 Oct;2009(1):27-40.

PMID:
20144450
31.

Calibration of European pharmacopoeia biological reference preparation for diphtheria vaccine (adsorbed) batch 4.

Stickings P, Rigsby P, Buchheit KH, Sesardic D.

Pharmeur Bio Sci Notes. 2009 Oct;2009(1):1-9.

PMID:
20144448
32.

A review of the international issues surrounding the availability and demand for diphtheria antitoxin for therapeutic use.

Wagner KS, Stickings P, White JM, Neal S, Crowcroft NS, Sesardic D, Efstratiou A.

Vaccine. 2009 Dec 10;28(1):14-20. doi: 10.1016/j.vaccine.2009.09.094. Epub 2009 Oct 7. Review.

PMID:
19818425
33.

Development and use of a novel in vitro assay for testing of diphtheria toxoid in combination vaccines.

Coombes L, Stickings P, Tierney R, Rigsby P, Sesardic D.

J Immunol Methods. 2009 Oct 31;350(1-2):142-9. doi: 10.1016/j.jim.2009.09.002. Epub 2009 Sep 15.

PMID:
19761770
34.

TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines.

Sayin B, Somavarapu S, Li XW, Sesardic D, Senel S, Alpar OH.

Eur J Pharm Sci. 2009 Nov 5;38(4):362-9. doi: 10.1016/j.ejps.2009.08.010. Epub 2009 Sep 4.

PMID:
19733658
35.

Measurement of botulinum types A, B and E neurotoxicity using the phrenic nerve-hemidiaphragm: improved precision with in-bred mice.

Rasetti-Escargueil C, Jones RG, Liu Y, Sesardic D.

Toxicon. 2009 Apr;53(5):503-11. doi: 10.1016/j.toxicon.2009.01.019.

PMID:
19673096
36.

New highly specific botulinum type C1 endopeptidase immunoassays utilising SNAP25 or Syntaxin substrates.

Jones RG, Liu Y, Sesardic D.

J Immunol Methods. 2009 Mar 31;343(1):21-7. doi: 10.1016/j.jim.2009.01.001. Epub 2009 Jan 25.

PMID:
19176217
37.

Transcutaneous immunisation assisted by low-frequency ultrasound.

Dahlan A, Alpar HO, Stickings P, Sesardic D, Murdan S.

Int J Pharm. 2009 Feb 23;368(1-2):123-8. doi: 10.1016/j.ijpharm.2008.10.014. Epub 2008 Nov 1.

PMID:
19013510
38.

Transcutaneous delivery of tetanus toxin Hc fragment induces superior tetanus toxin neutralizing antibody response compared to tetanus toxoid.

Johnston L, Mawas F, Tierney R, Qazi O, Fairweather N, Sesardic D.

Hum Vaccin. 2009 Apr;5(4):230-6. Epub 2009 Apr 28.

PMID:
18948742
39.

Optimization of the formulation for a candidate lyophilised tetanus toxoid reference preparation.

Matejtschuk P, Malik K, Tierney R, Sloth Wilhelmsen E, Preneta-Blanc R, Rigsby P, Sesardic D.

Biologicals. 2009 Jan;37(1):1-7. doi: 10.1016/j.biologicals.2008.07.006. Epub 2008 Sep 19.

PMID:
18805022
40.

Calibration of replacement international standards of diphtheria and tetanus toxoids for use in flocculation test.

Preneta-Blanc R, Rigsby P, Wilhelmsen ES, Tierney R, Brierley M, Sesardic D.

Biologicals. 2008 Sep;36(5):315-26. doi: 10.1016/j.biologicals.2008.05.002. Epub 2008 Aug 3.

PMID:
18676158
41.

Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.

Sayin B, Somavarapu S, Li XW, Thanou M, Sesardic D, Alpar HO, Senel S.

Int J Pharm. 2008 Nov 3;363(1-2):139-48. doi: 10.1016/j.ijpharm.2008.06.029. Epub 2008 Jul 9.

PMID:
18662762
42.

An improved method for development of toxoid vaccines and antitoxins.

Jones RG, Liu Y, Rigsby P, Sesardic D.

J Immunol Methods. 2008 Aug 20;337(1):42-8. doi: 10.1016/j.jim.2008.05.009. Epub 2008 Jun 9.

PMID:
18571196
43.

Transcutaneous immunization with cross-reacting material CRM(197) of diphtheria toxin boosts functional antibody levels in mice primed parenterally with adsorbed diphtheria toxoid vaccine.

Stickings P, Peyre M, Coombes L, Muller S, Rappuoli R, Del Giudice G, Partidos CD, Sesardic D.

Infect Immun. 2008 Apr;76(4):1766-73. doi: 10.1128/IAI.00797-07. Epub 2008 Jan 28.

44.

Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins.

Jones RG, Ochiai M, Liu Y, Ekong T, Sesardic D.

J Immunol Methods. 2008 Jan 1;329(1-2):92-101. Epub 2007 Oct 23.

PMID:
17976638
45.

New adjuvants: EU regulatory developments.

Sesardic D, Rijpkema S, Patel BP.

Expert Rev Vaccines. 2007 Oct;6(5):849-61. Review.

PMID:
17931163
46.

Collaborative study for the validation of serological methods for potency testing of diphtheria toxoid vaccine (part 2).

Winsnes R, Sesardic D, Daas A, Behr-Gross ME.

Pharmeuropa Bio. 2006 Nov;2006(1):73-88.

PMID:
17270133
47.

Botulinum type A toxin neutralisation by specific IgG and its fragments: a comparison of mouse systemic toxicity and local flaccid paralysis assays.

Jones RG, Alsop TA, Hull R, Tierney R, Rigsby P, Holley J, Sesardic D.

Toxicon. 2006 Sep 1;48(3):246-54. Epub 2006 Jun 14.

PMID:
16870221
48.

Reduction of the ganglioside binding activity of the tetanus toxin HC fragment destroys immunogenicity: implications for development of novel tetanus vaccines.

Qazi O, Sesardic D, Tierney R, Söderbäck Z, Crane D, Bolgiano B, Fairweather N.

Infect Immun. 2006 Aug;74(8):4884-91.

49.

Regulatory considerations on new adjuvants and delivery systems.

Sesardic D.

Vaccine. 2006 Apr 12;24 Suppl 2:S2-86-7. Review.

PMID:
16823940
50.

Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine.

Aguila A, Donachie AM, Peyre M, McSharry CP, Sesardic D, Mowat AM.

Vaccine. 2006 Jun 12;24(24):5201-10. Epub 2006 Apr 17.

PMID:
16650917

Supplemental Content

Loading ...
Support Center